Form 4: Aclaris Therapeutics CFO Kevin Balthaser Reports Stock Transactions
SEC Form 4 Filing
Kevin Balthaser, CFO of Aclaris Therapeutics, reports the vesting and settlement of restricted stock units and associated tax withholding.
Summary
- On September 1, 2024, Kevin Balthaser, the Chief Financial Officer of Aclaris Therapeutics, Inc., had 1,000 restricted stock units vest and settle into common stock.
- The company withheld 286 shares at a price of $1.18 to cover Balthaser's tax obligations related to the vesting.
- Following these transactions, Balthaser directly owns 24,697 shares of Aclaris Therapeutics common stock.
Sentiment
Score: 5
Explanation: This is a routine filing related to executive compensation, with no particularly positive or negative implications.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates activity related to equity compensation.
Stakeholder Impact
- Shareholders are informed about insider transactions, contributing to market transparency.
Key Dates
| Date | Description |
|---|---|
| 09/01/2024 | Restricted stock units vested and settled; tax withholding occurred. |
| 09/04/2024 | Form 4 filing date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.